Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vaxxinity, Inc. (VAXX)

2.34   -0.03 (-1.27%) 03-22 11:02
Open: 2.39 Pre. Close: 2.37
High: 2.39 Low: 2.24
Volume: 23,744 Market Cap: 295(M)

Technical analysis

as of: 2023-03-22 10:50:07 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.04     One year: 3.56
Support: Support1: 2.15    Support2: 1.87
Resistance: Resistance1: 2.6    Resistance2: 3.04
Pivot: 2.2
Moving Average: MA(5): 2.19     MA(20): 2.23
MA(100): 2.16     MA(250): 2.54
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 51.3     %D(3): 40.1
RSI: RSI(14): 49.8
52-week: High: 8.35  Low: 1.24
Average Vol(K): 3-Month: 350 (K)  10-Days: 146 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VAXX ] has closed below upper band by 27.1%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.41 - 2.43 2.43 - 2.44
Low: 2 - 2.02 2.02 - 2.03
Close: 2.34 - 2.37 2.37 - 2.39

Company Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Headline News

Wed, 01 Mar 2023
ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena ... - Business Wire

Thu, 09 Feb 2023
Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas - The Business Journals

Mon, 23 Jan 2023
Vaxxinity up 23% as 2023 surge continues; up 158% year to date ... - Seeking Alpha

Thu, 19 Jan 2023
Why Shares of Vaxxinity Jumped This Week - Nasdaq

Thu, 05 Jan 2023
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference - Yahoo Finance

Thu, 10 Nov 2022
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -26 (M)
Shares Float 0 (M)
% Held by Insiders 1.1218e+008 (%)
% Held by Institutions 3.265e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.87e+006
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.39
Profit Margin (%) 0
Operating Margin (%) 10
Return on Assets (ttm) 290
Return on Equity (ttm) 600
Qtrly Rev. Growth -118.1
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.79
Qtrly Earnings Growth -1.0159e+008
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0.1
Price to Book value -1.7
Price to Sales 3894.87
Price to Cash Flow 0

Stock Dividends

Dividend 932660
Forward Dividend 957060
Dividend Yield 39857300%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.